Skip to Content


Active Substance: levacetylmethadol
Common Name: levacetylmethadol
ATC Code: N02AC
Marketing Authorisation Holder: Sipaco Internacional Lda.
Active Substance: levacetylmethadol
Status: Withdrawn
Authorisation Date: 1997-07-01
Therapeutic Area: Opioid-Related Disorders
Pharmacotherapeutic Group: Analgesics

Therapeutic Indication

ORLAAM is indicated for the substitution maintenance treatment of opiate addiction in adults previously treated with methadone, as part of a comprehensive treatment plan including medical, social and psychological care.

ORLAAM should be administered under the supervision of physicians with experience in addiction treatment and whenever practicable, in centres specialising in the treatment of drug addiction.

ORLAAM is not intended for take home use.

The marketing authorisation for Orlaam has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.